Münchener Kardiologe erhält den diesjährigen Präventionspreis der DGIM: Bei wem…
AUSSCHREIBUNG: OTSUKA TEAM AWARD PSYCHIATRY+ 2020
Jetzt um den bytes4diabetes-Award 2021 bewerben
Bayer verleiht PHILOS-Preis an Wegbegleiter von Menschen mit Hämophilie
bytes4diabetes-Awards 2020 gehen an vier innovative Digital-Projekte
Deutscher Pflegetag und Zukunftsforum Geburtshilfe am 11.-12. November 2020
Virtueller DIVI-Kongress ist ein Novum für 6.000 Teilnehmer
More questions than answers remain concerning effects of airplane travel on insulin pump delivery
New Rochelle, NY, USA (August 30, 2011) — Despite recent concerns that changes in atmospheric pressure during airplane travel may affect the amount of insulin delivered via pump devices, the current evidence is limited and it would be unwise to overreact until more data are available, according to an insightful editorial in Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. The editorial is available free online.
Irl B. Hirsch, MD, Professor of Medicine, University of Washington School of Medicine (Seattle), and Senior Editor of Diabetes Technology & Therapeutics penned a thoughtful editorial commenting on a recent article by King et al., in which the authors simulated the effects of changes in atmospheric pressure in a hypobaric chamber and reported the delivery of improper amounts of insulin to a small number of patients with type 1 diabetes who used insulin pumps.
"This study was implemented in such a small number of people that large conclusions may not be justified," writes Dr. Hirsch. "It is possible the authors overreacted in their recommendations," he adds, suggesting that their recommendations be viewed with skepticism as they are not supported by data or practical advice.
While the paper by King et al. provides one possible explanation for why blood glucose levels may fluctuate in patients using insulin pumps, it has several limitations, including the very small changes in insulin delivery that occurred during the simulations.
Diabetes Technology & Therapeutics is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Technologies include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Complete tables of content and a free sample issue may be viewed online.
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Metabolic Syndrome and Related Disorders, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on our website
Diabetes Technology & Therapeutics, 30.08.2011 (tB).